![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1402534
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Á¡¾È¾à ½ÃÀå ¿¹Ãø(-2030³â) : Áö¿ªº° ºÐ¼® - À¯Çü, ¿ëµµ, ±¸ÀÔ ¹æ¹ýº°Asia Pacific Eye Drops Market Forecast to 2030 - Regional Analysis - by Type (Antibiotics, Artificial Tears, Hormones, and Others), Application, and Purchase Mode (OTC and Prescription) |
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Á¡¾È¾à ½ÃÀåÀº 2022³â 28¾ï 2,384¸¸ ´Þ·¯¿¡¼ 2030³â¿¡´Â 43¾ï 8,659¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. 2022-2030³âÀÇ CAGRÀº 5.7%·Î ÃßÁ¤µË´Ï´Ù.
¾ÆÀÌÄÉ¾î ±¸»óÀÇ Áõ°¡°¡ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Á¡¾È¾à ½ÃÀåÀ» Áö¿ø
ÃÖ±Ù ¾È°ú Áúȯ¿¡ ´ëÇÑ ÀÎ½Ä °³¼±°ú °è¸ùÀ» À§ÇØ ´Ù¾çÇÑ ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸¸ç, ȯÀÚµéÀº ÀûÀýÇÑ ¾à¹°°ú Ä¡·á¹ýÀ» ÀÌ¿ëÇϰí ÀÖ½À´Ï´Ù.
±¹Á¦ÀûÀÎ ºñÁ¤ºÎ±â±¸ÀÎ Sightsavers´Â °³¹ßµµ»ó±¹¿¡¼ ¾ÈÁúȯÀ» Ä¡·áÇÏ°í ¿¹¹æÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. Àεµ¿¡¼´Â ¸¹Àº »ç¶÷µéÀÌ ³óÃÌ¿¡ »ì°í ÀÖÀ¸¸ç, ¾ÈÁúȯ¿¡ ´ëÇÑ ÀνÄÀÌ ³·°Å³ª ¾Æ¿¹ ¾ø´Â °æ¿ì°¡ ¸¹Àºµ¥, ½ÃÃ÷¼¼À̹ö½º´Â ³óÃÌ ¾Èº¸°Ç ÇÁ·Î±×·¥À» ÅëÇØ ÀνÄÀ» ³ôÀÌ°í ¾çÁúÀÇ ¾È°ú ÀÇ·á ¼ºñ½º¸¦ Á¦°øÇÏ¿© ³óÃÌ ÁÖ¹ÎÀÇ ÇÇÇÒ ¼ö ÀÖ´Â ½Ç¸íÀ» ±ÙÀýÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ¶ÇÇÑ 2019³â WHO´Â 'º¸ÆíÀû °Ç° º¸Àå ¹× ¾È°ú ÀÇ·á'¸¦ ½ÃÀÛÇß½À´Ï´Ù. ÀÌ Çà»ç´Â WHOÀÇ '¼¼°è ½Ã·Â º¸°í¼'ÀÇ ±Ç°í»çÇ×À» °èȹÇϰí À̵¿ÇÏ´Â µ¥ ÀÖÀ¸¸ç, WHO ȸ¿ø±¹À» Áö¿øÇϱâ À§ÇØ ½Ç¿ëÀûÀÌ°í ´Ü°èÀûÀÎ ÁöħÀ» Á¦°øÇÏ´Â Çà»ç·Î, WHO´Â »ç¶÷ Áß½ÉÀÇ Á¾ÇÕÀûÀÎ ¾È°ú ÀÇ·á ¼ºñ½º¸¦ Á¦°øÇϱâ À§ÇØ ÀÌ Çà»ç¸¦ ½ÃÀÛÇß½À´Ï´Ù. ¶ÇÇÑ Àεµ-¹Ì±¹ °øµ¿ ½Ã·Â Á¶»ç ÇÁ·Î±×·¥ 2020Àº ½Ç¸í À§Çè ¾ÈÁúȯ, ½Ã°¢ Àå¾Ö ¹× °ü·Ã ÇÕº´ÁõÀ» ÀÌÇØÇÏ°í ¿¹¹æÇϰí Ä¡·áÇÏ´Â µ¥ ÇʼöÀûÀÎ °úÇÐ ±â¼ú °³¹ß¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. Àεµ »ý¸í°øÇÐºÎ¿Í ¹Ì±¹ ±¹¸³º¸°Ç¿ø(NIH)ÀÌ ÀÌ ¿¬±¸ ÇÁ·Î±×·¥¿¡ ÀÚ±ÝÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù.
2021³â 12¿ù, NIH´Â ÄÌ·Î±× ¾È°ú ¼¾ÅÍ¿Í Àεµ ¾Æ¶óºóµå ¾È°ú º´¿øÀÇ ÆÄÆ®³Ê½ÊÀ» Áö¿øÇÏ¿© ¾È°ú Àü¹®ÀǸ¦ À§ÇÑ ÀÓ»ó ¿¬±¸ ±³À° ÇÁ·Î±×·¥À» °³¹ßÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ±³À° ÇÁ·Î±×·¥Àº ÀεµÀÇ ¾È°ú ÀÇ·á ºÐ¾ß¸¦ ¹ßÀü½ÃŰ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ÀÌó·³ ¾È°ú ¿¬±¸¿¡ ´ëÇÑ ÀÚ±ÝÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Á¡¾ÈÁ¦ ½ÃÀå ±â¾÷¿¡°Ô ¼ºÀå ±âȸ¸¦ Á¦°øÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾ç Á¡¾ÈÁ¦ ½ÃÀå °³¿ä
¾Æ½Ã¾ÆÅÂÆò¾ç Á¡¾ÈÁ¦ ½ÃÀåÀº Áß±¹, ÀϺ», Àεµ, È£ÁÖ, Çѱ¹ ¹× ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀ¸·Î ¼¼ºÐȵ˴ϴÙ. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ Áß °¡Àå ºü¸¥ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå ¼ºÀåÀº È£ÁÖ¿Í Àεµ¿Í °°Àº ±¹°¡¿¡¼ ¾È±¸°ÇÁ¶Áõ À¯º´·üÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ ³ëÀÎ Àα¸ Áõ°¡, ÀÇ·á ÀÎÇÁ¶ó °³¹ß, ¿¬±¸ Ȱµ¿À» ÃËÁøÇÏ´Â ÅõÀÚ Áõ°¡´Â ¿¹Ãø ±â°£ Áß ¾Æ½Ã¾ÆÅÂÆò¾ç ¾È¾à ½ÃÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Áß±¹¿¡¼´Â ¸Å³â ¾à 20-30%ÀÇ »ç¶÷µéÀÌ ¾È±¸°ÇÁ¶Áõ Áø´ÜÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¾È±¸°ÇÁ¶ÁõÀ» À¯¹ßÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â ÄÄÇ»ÅÍ, ³ëÆ®ºÏ, ÈÞ´ëÆùÀ» Àå½Ã°£ »ç¿ëÇÏ´Â °ÍÀ» µé ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ³ôÀº ´ë±â¿À¿° ¼öÁصµ ¾È±¸°ÇÁ¶ÁõÀÇ ÁÖ¿ä ¿øÀÎÀ¸·Î ²ÅÈü´Ï´Ù. Áß±¹Àº ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼ ¾È±¸°ÇÁ¶ÁõÀ» À¯¹ßÇÒ ¼ö ÀÖ´Â ´ç´¢º´°ú ³ì³»Àå ¹ßº´·üÀÌ °¡Àå ³ô½À´Ï´Ù. Áß±¹Àº ¶ÇÇÑ ¿ø·áÀǾàǰ Á¦Á¶ ¹× Á¦³×¸¯ ÀǾàǰÀÇ ÃÖ´ë ½ÃÀåÀ̱⵵ ÇÕ´Ï´Ù. 2023³â 4¿ù, Ocumension Therapeutics´Â Zerviate 0.24%(¼¼Æ¼¸®Áø) Á¡¾È¾×¿¡ ´ëÇÑ Áß±¹ ½ÃÆÇÇã°¡ ½Åû(NDA)À» Á¦ÃâÇß½À´Ï´Ù. ÀÌ ¾È¾àÀº ÁÖ·Î ¾Ë·¹¸£±â¼º °á¸·¿°À¸·Î ÀÎÇÑ ´«ÀÇ °¡·Á¿òÁõÀ» ¾ïÁ¦ÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù.
Áß±¹ÀÇ ¾Æ½Ã¾ÆÅÂÆò¾ç Á¡¾ÈÁ¦ ½ÃÀåÀº ±¹³»¿Ü Á¦¾àȸ»çµéÀÌ ÁøÃâÇØ ÀÖÀ¸¸ç, °æÀïÀÌ Ä¡¿ÇÕ´Ï´Ù. Áß±¹³» À¯¸í ¾È¾à ºê·£µå·Î´Â »êÅÙ(Santen), ³ë¹ÙƼ½º(Novartis), ¾ËÄÜ(Alcon), ¾Ë·¯°£(Allergan), ¹Ù¿ì½¬·Ò(Baush Lomb) µîÀÌ ÀÖÀ¸¸ç, ó¹æÀü ±â¹Ý ¾È¾à°ú ÀϹÝÀǾàǰ(OTC) µî ´Ù¾çÇÑ ¾È°ú Á¦Ç°À» Á¦°øÇÕ´Ï´Ù. Á¦Ç°À» Á¦°øÇÕ´Ï´Ù. Áß±¹³» ¾È¾à À¯Åë °æ·Î¿¡´Â º´¿ø, Ŭ¸®´Ð, ¾à±¹, E-Commerce Ç÷§Æû µîÀÌ ÀÖ½À´Ï´Ù. º´¿ø ¹× Áø·á¼Ò´Â ÀϹÝÀûÀ¸·Î ó¹æÀü ±â¹Ý Á¡¾ÈÁ¦¸¦ Á¦°øÇÏ´Â ±â¾÷ÀÇ À¯Åë¾÷üÀ¸·Î ¼±È£µÇ¸ç, OTC Á¡¾ÈÁ¦´Â ¾à±¹À̳ª ¿Â¶óÀÎ Ç÷§Æû¿¡¼ ½±°Ô ±¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Á¡¾È¾à ½ÃÀå ¸ÅÃâ°ú 2030³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Á¡¾È¾à ½ÃÀå ¼¼ºÐÈ
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Á¡¾È¾à ½ÃÀåÀº À¯Çü, ¿ëµµ, ±¸ÀÔ ÇüÅÂ, ±¹°¡·Î ±¸ºÐµË´Ï´Ù.
À¯Çüº°·Î´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Á¡¾È¾à ½ÃÀåÀº Ç×»ýÁ¦, Àΰø´«¹°, È£¸£¸óÁ¦, ±âŸ·Î ±¸ºÐµË´Ï´Ù. 2022³â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Á¡¾È¾à ½ÃÀå¿¡¼´Â Ç×»ýÁ¦ ºÐ¾ß°¡ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
¿ëµµº°·Î´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Á¡¾È¾à ½ÃÀåÀº ¾ÈÁúȯ, ¾ÆÀÌÄɾî, ±âŸ·Î ±¸ºÐµË´Ï´Ù. 2022³â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Á¡¾È¾à ½ÃÀå¿¡¼´Â ¾ÈÁúȯ ºÐ¾ß°¡ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¾ÈÁúȯ ºÎ¹®Àº ¶ÇÇÑ ¾È±¸°ÇÁ¶Áõ, ³ì³»Àå, ¹é³»Àå, ±âŸ·Î ±¸ºÐµË´Ï´Ù.
±¸ÀÔ ÇüÅ¿¡ ±â¹ÝÇÏ¿© ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Á¡¾È¾à ½ÃÀåÀº OTC¿Í ó¹æÀüÀ¸·Î ±¸ºÐµË´Ï´Ù. 2022³â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Á¡¾È¾à ½ÃÀå¿¡¼´Â ó¹æÀü ºÎ¹®ÀÌ º¸´Ù Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
±¹°¡º°·Î´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Á¡¾È¾à ½ÃÀåÀº Áß±¹, ÀϺ», Àεµ , È£ÁÖ, Çѱ¹, ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀ¸·Î ±¸ºÐµË´Ï´Ù. 2022³â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Á¡¾È¾à ½ÃÀåÀº Áß±¹ÀÌ µ¶Á¡Çϰí ÀÖ½À´Ï´Ù.
AbbVie Inc, Alcon AG, Bausch &Lomb Inc, Biomedica Pvt Ltd, Pfizer Inc, Prestige Consumer Healthcare Inc, Rohto Pharmaceutical Co Ltd µîÀÌ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Á¡¾È¾à ½ÃÀå¿¡¼ »ç¾÷À» ¿î¿µÇϰí ÀÖ´Â ´ë±â¾÷ÀÔ´Ï´Ù.
The Asia Pacific eye drops market is expected to grow from US$ 2,823.84 million in 2022 to US$ 4,386.59 million by 2030. It is estimated to grow at a CAGR of 5.7% from 2022 to 2030.
Rising Initiatives for Eye Care Fuels Asia Pacific Eye Drops Market
In recent years, various measures and efforts have been taken to create awareness and educate people regarding eye diseases, prompting patients to access suitable medications and treatments.
Sightsavers-an international nongovernmental organization-works in developing countries to treat and prevent eye diseases. A large population in India resides in rural areas with limited or no awareness of eye ailments. Sightsavers aims to create awareness with its Rural Eye Health Programme, provide high-quality eye health services, and eradicate avoidable blindness in the rural population. In addition, in 2019, the WHO launched the Universal Health Coverage and Eye Care: Promoting Country Action, an event to provide practical, step-by-step guidance to support Member States of WHO in planning and implementing the recommendations of the WHO's World Report on vision. The WHO launched this event to provide integrated people-centered eye care services. Further, the India-US Collaborative Vision Research Program 2020 focuses on advancing science and technology crucial to understand, prevent, and treat blinding eye diseases, visual disorders, and associated complications. The Indian Department of Biotechnology and the US NEI fund this research program.
In December 2021, NIH-funded projects supported the partnership between Kellogg Eye Center and Aravind Eye Hospital (India) to develop a clinical research training program for eyecare specialists. Such training programs are meant to develop the eyecare field in India. Thus, increasing funds for eyecare research will likely offer growth opportunities to the eye drop market players.
Asia Pacific Eye Drops Market Overview
The Asia Pacific eye drops market is sub segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Asia Pacific is expected to register the fastest CAGR during the forecast period. The growth of the market in Asia Pacific is attributed to the growing prevalence of dry eye diseases in countries such as Australia, and India. Additionally, the growing geriatric population, developing healthcare infrastructure, and increasing investments to boost research activities are projected to drive the Asia Pacific eye drops market during the forecast period. In China, every year about 20-30% of people are diagnosed with dry eye conditions. Major factors causing dry eye condition include long spending hours in front of computers, laptops, and mobile phones. Moreover, high air pollution level is another leading cause of dry eye condition in the country. The country records the highest incidences of diabetes and glaucoma in Asia Pacific, which may lead to a dry eye condition. China is also the largest market for API manufacturing and generic pharmaceuticals. Various companies in the country are involved in the production of ophthalmic products. In April 2023, Ocumension Therapeutics submitted a new drug application (NDA) for approval to commercialize Zerviate 0.24% (cetirizine) ophthalmic solution in China. This solution is majorly used to reduce ocular itching associated with allergic conjunctivitis.
The Asia Pacific eye drops market in China is quite competitive, with the presence of both domestic and international pharmaceutical companies. A few of the well-known domestic eye drop brands in the country are Santen, Novartis, Alcon, Allergan, and Baush + Lomb, which offer a range of eye care products, including prescription-based eye drops and over the counter (OTC) solutions. The distribution channels for eye drops in China include hospitals, clinics, pharmacies, and e-commerce platforms. Hospitals and clinics are commonly preferred as distributors by companies offering prescription-based eye drops, while OTC eye drops are readily available in pharmacies and online platforms.
Asia Pacific Eye Drops Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Eye Drops Market Segmentation
The Asia Pacific eye drops market is segmented into type, application, purchase mode, and country.
Based on type, the Asia Pacific eye drops market is segmented into antibiotics, artificial tears, hormones, and others. The antibiotics segment held the largest share of the Asia Pacific eye drops market in 2022.
Based on application, the Asia Pacific eye drops market is segmented into eye diseases, eye care, and others. The eye diseases segment held the largest share of the Asia Pacific eye drops market in 2022. The eye diseases segment is further segmented into dry eye, glaucoma, cataract, and others.
Based on purchase mode, the Asia Pacific eye drops market is segmented into OTC and prescription. The prescription segment held a larger share of the Asia Pacific eye drops market in 2022.
Based on country, the Asia Pacific eye drops market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific eye drops market in 2022.
AbbVie Inc, Alcon AG, Bausch & Lomb Inc, Biomedica Pvt Ltd, Pfizer Inc, Prestige Consumer Healthcare Inc., and Rohto Pharmaceutical Co Ltd are some of the leading companies operating in the Asia Pacific eye drops market.